Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aleglitazar in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age;~* type 2 diabetes, diagnosed \>=1 month of screening;~* either drug-naive, or pretreated with a maximum of 2 oral antihyperglycemic agents at submaximal doses;~* HbA1c \<=10.0% at screening, and 7.0-10.0% at pre-randomisation visit.~Exclusion Criteria:~* type 1 diabetes;~* currently or previously treated with insulin, a thiazolidinedione, or a dual Peroxisome Proliferator Activated Receptor (PPAR) agonist;~* clinically significant cardiovascular disease;~* Congestive Heart Failure (CHF) New York Heart Association (NYHA) 3-4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Actos (Type: ACTIVE_COMPARATOR): None
- Aleglitazar 1 (Type: EXPERIMENTAL): None
- Aleglitazar 2 (Type: EXPERIMENTAL): None
- Aleglitazar 3 (Type: EXPERIMENTAL): None
- Aleglitazar 4 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).